Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • Sibrotuzumab - Colorectal Neoplasms
    Clinical Study Number 1152.10
    Study Indication Colorectal Neoplasms
    Product Sibrotuzumab
    Generic Name Sibrotuzumab
    Lab Code
    Clinical Phase IIa
    Study Title

    A phase II uncontrolled study to evaluate the antitumour activity and safety of intravenous BIBH 1, administered in a weekly dose of 100 mg in 12 weeks, in patients with metastatic colorectal cancer.

    Study Document
    Trial synopsis 1152.10_CO english
  • Sibrotuzumab - Carcinoma, Non-Small-Cell Lung
    Clinical Study Number 1152.3
    Study Indication Carcinoma, Non-Small-Cell Lung
    Product Sibrotuzumab
    Generic Name Sibrotuzumab
    Lab Code
    Clinical Phase I
    Study Title

    A Phase I Single Dose Escalation Study of BIBH 1 in Patients with Non-Small Cell Lung Cancer Scheduled for Resection

    Study Document
    Trial synopsis 1152.3_CO english
  • Sibrotuzumab - Carcinoma, Non-Small-Cell Lung
    Clinical Study Number 1152.6
    Study Indication Carcinoma, Non-Small-Cell Lung
    Product Sibrotuzumab
    Generic Name Sibrotuzumab
    Lab Code
    Clinical Phase I
    Study Title

    A Phase I Single Dose Escalation Study of 131 I-Sibrotuzumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Study Document
    Trial synopsis 1152.6_CO english